What is the best approach to manage a 62-year-old man with a random plasma glucose of 300 mg/dL, a history of cerebrovascular accident and hypertension, who refuses insulin due to needle phobia?

Initiate a GLP-1 Receptor Agonist Instead of Insulin

For this 62-year-old man with random glucose of 300 mg/dL refusing insulin due to needle phobia, start with an oral GLP-1 receptor agonist (oral semaglutide) or, if injectable therapy is acceptable, a once-weekly GLP-1 RA, given his cardiovascular history (prior stroke). While current guidelines typically recommend insulin as first-line therapy at glucose ≥300 mg/dL 1, the patient's absolute refusal of needles and significant cardiovascular disease history make GLP-1 RAs the pragmatic and medically sound alternative that addresses both glycemic control and cardiovascular risk reduction.

Why This Approach Makes Sense

The 2025 ADA guidelines state that insulin should be considered first-line when glucose levels are ≥300 mg/dL 1. However, these same guidelines explicitly recognize that when selecting between injectable therapies, individual preference matters 1. A patient with needle phobia who refuses insulin will not benefit from a medication they won't take—this creates a therapeutic dead-end that worsens both morbidity and mortality.

The Cardiovascular Advantage

This patient's history of cerebrovascular accident is critical. GLP-1 RAs with proven cardiovascular benefit should be prioritized in patients with established CVD 1. His stroke history places him at extremely high risk for recurrent cardiovascular events, and GLP-1 RAs offer:

• Proven reduction in major adverse cardiovascular events
• Stroke risk reduction specifically
• No hypoglycemia risk (unlike insulin)
• Weight loss benefit (if applicable)

Practical Implementation Strategy

Start with oral semaglutide if the patient is truly needle-phobic:

• Begin at 3 mg daily for 30 days
• Increase to 7 mg daily for at least 30 days
• Target maintenance dose of 14 mg daily
• This completely avoids needles while providing robust A1C reduction (1.5-2.0%)

If the patient can tolerate once-weekly injections (many needle-phobic patients find weekly preferable to daily):

• Consider dulaglutide 1.5 mg weekly (single-use pen, no needle visualization)
• Or semaglutide 0.5 mg weekly, titrating to 1 mg
• These offer superior A1C reduction compared to oral formulations

Addressing the Acute Hyperglycemia

While glucose of 300 mg/dL is concerning, this patient is not in DKA or HHS (no mention of ketones, severe dehydration, or altered mental status). The immediate risk is not so severe that forcing insulin on a refusing patient is warranted. Instead:

• Add metformin immediately if not contraindicated (check renal function, no contrast studies planned)
• Consider SGLT2 inhibitor for additional cardiovascular and renal protection, though monitor for euglycemic DKA
• Reinforce lifestyle modifications aggressively during the GLP-1 RA titration period

Managing the Transition Period

The 2-3 month titration period for GLP-1 RAs means glucose will remain elevated initially. To bridge this gap:

1. Maximize oral agents first: Metformin up to 2000 mg daily (if tolerated), potentially add SGLT2 inhibitor
2. Intensive glucose monitoring: Daily fasting and 2-hour post-prandial checks
3. Aggressive lifestyle intervention: This is not optional—dietary modification can drop glucose 50-100 mg/dL within weeks
4. Set a decision point: If glucose remains >250 mg/dL after 6 weeks despite maximal oral therapy and GLP-1 RA titration, revisit the insulin discussion with emphasis on newer delivery systems

Common Pitfalls to Avoid

Don't dismiss needle phobia as "non-compliance": This is a legitimate psychological barrier that, if ignored, leads to treatment failure and worse outcomes. Forcing insulin on a refusing patient results in missed doses, erratic control, and dangerous glucose variability.

Don't delay GLP-1 RA initiation: The cardiovascular benefits take time to manifest. Starting early, even with suboptimal initial glucose control, provides long-term mortality benefit in this stroke patient 1.

Don't forget glucagon prescription: Even without insulin, severe hypoglycemia can occur with aggressive oral agent combinations. Prescribe glucagon nasal spray or injectable for emergency use.

When Insulin Becomes Unavoidable

If this approach fails and glucose remains dangerously elevated (consistently >350 mg/dL with symptoms), explore these needle-phobia workarounds:

• Inhaled insulin (Afrezza) for prandial coverage—no needles required
• Insulin pump therapy with insertion assistance—once placed, no daily injections
• Psychological intervention: Formal needle phobia therapy (systematic desensitization) while using oral agents as bridge
• V-Go wearable insulin device: Single daily application, continuous delivery, no multiple injections

The key is that insulin refusal in this context is not absolute—it's a barrier to work around while optimizing cardiovascular protection through GLP-1 RA therapy.